BRD2 and endometrial cancer: Altogether, the analysis of the exosome proteome from type I EC suggests that endometrial cancer cells to grow are exploiting all such strategies (including the cross-talk with platelets and NAT, cancer metabolism rewiring, and antioxidant response) to evade cellular and immune checkpoints.